Skip to main content

Treatment Clinical Trials for Acute Myeloid Leukemia (AML)

Review the acute myeloid leukemia (aml) treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 151-175 of 290

Standard-of-Care Reduced-Intensity Conditioning with Total Body Irradiation for the Treatment of Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Stem Cell Transplant in Treating Patients with Blood Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Decitabine and Venetoclax for Maintenance Treatment in Patients with AML and MDS After Donor Stem Cell Transplant
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Bortezomib in Combination with CPX-351 for the Treatment of Newly-Diagnosed TP53- Mutated Acute Myeloid Leukemia
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Momelotinib in Combination with Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Universal Donor Natural Killer Cells for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, KARMA Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Decitabine/Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tagraxofusp and Combination Chemotherapy for the Treatment of CD123-Positive Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nadunolimab and Azacitidine With or Without Venetoclax for the Treatment of Patients with Myelodysplastic Syndrome or Relapsed or Refractory Acute Myelogenous Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
SNDX-5613 with Decitabine/Cedazuridine, and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, SAVE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Modified Memory-Like NK Cells and TCRαβ T-cell Depleted Half-Matched Related Donor Transplant for the Treatment of High-Risk Acute Myeloid Leukemia (ABCD NK trial)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PRAME-TCR-NK Cells with Lymphodepleting Chemotherapy for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ONC201 Alone or in Combination with Venetoclax in Treating Patients with Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas